肝硬化顽固性腹水治疗现状  

Treatment of refractory ascites in patients with liver cirrhosis

作　　者：张鑫赫(综述) 李异玲(审校)[1] Zhang Xinhe;Li Yiling(Department of gastroenterology,First Affiliated Hospital,China Medical University,Shenyang 110001,Liaoning Province)

机构地区：[1]中国医科大学附属第一医院消化内科,沈阳市110001

出　　处：《实用肝脏病杂志》2020年第5期757-760,共4页Journal of Practical Hepatology

摘　　要：目的腹水是失代偿期肝硬化的常见表现,其中顽固性腹水的发病率为5%~10%,患者生存率低。国内外大量研究对顽固性腹水的治疗进行了研究报道,并取得了一定的进展。本文针对目前顽固性腹水的治疗现状和进展进行了较为系统的综述。Objective Ascites is a common manifestation of decompensated liver cirrhosis.The incidence of refractory ascites(RA)in patients with cirrhosis is about 5%to 10%,and the survival of patients with RA is low.A number of studies at home and abroad have reported the progress of treatment on RA.We reviewed the current treatment of RA in patients with cirrhosis.

关 键 词：顽固性腹水 腹腔穿刺大量放腹水 经颈静脉肝内门体分流术 特利加压素 托伐普坦 

分 类 号：R57[医药卫生—消化系统]